Background {#Sec1}
==========

Patients with chronic myeloid leukemia (CML) typically present with high white blood cell (WBC) counts during an annual checkup, which is followed by abdominal discomfort from huge splenomegaly \[[@CR1]\]. Leukemic arthritis (LA), a rare manifestation of CML, is more likely in the advanced stage of the disease \[[@CR2]\]. Hypercalcemia associated with cancer is displayed by approximately 4% of patients with cancer, and it is mainly found in patients with solid tumors such as carcinoma (CA) of the lung, CA of the breast, and CA of the esophagus \[[@CR3]\]. Previous studies have reported an incidence of hypercalcemia of approximately 2.5% for all types of leukemia \[[@CR4]\]. Hypercalcemia in patients with CML is very rare, and only a limited number of cases have been reported, but if it occurs, there is a dismal prognosis \[[@CR4]\]. We present a patient with CML who developed these two uncommon manifestations (LA followed by severe symptomatic hypercalcemia) and an extensive review of the related literature.

Case presentation {#Sec2}
=================

A 35-year-old Thai man was diagnosed as having CML in the chronic phase in February 2016 during his annual checkup at a primary hospital; the diagnosis was confirmed with a cytogenetic study, which demonstrated 46,XY,t(9;22) \[[@CR5]\] and was positive for the *BCR-ABL* fusion gene. He was therefore referred to our hospital in July 2016 to receive definitive treatment of 400 mg/day of imatinib. After receiving imatinib, his treatment response was monitored by a real-time quantitative polymerase chain reaction (RQ-PCR) for the *BCR-ABL* gene using the international scale (IS) method. The results showed an optimal response was achieved at 3 and 6 months, according to the 2013 European LeukemiaNet recommendations, with RQ-PCRs for the *BCR-ABL* gene (IS unit) of 1.527% and 0.896%, respectively \[[@CR6]\]. During the treatment, he showed good compliance, and he did not use any herbs or other medications. He denied a family history with hematologic malignancies and he had no psychological problems.

In February 2017, however, he was admitted to our hospital with fever and severe pain in both knees and ankles of 5 days' duration. A physical examination showed symmetrical oligoarthritis in his knees and ankles. A complete blood count (CBC) revealed hemoglobin (Hb) of 6.5 g/dL, hematocrit (Hct) of 20.3%, a WBC count of 16.9 × 10^9^/L (49% neutrophils, 42% lymphocytes, 1% monocytes, 1% basophils, and 7% myeloblasts), and a platelet count of 16 × 10^9^/L. A synovial fluid analysis of his right knee showed a clear, colorless fluid with an absence of crystals and a WBC count of 180 cells/L, with 65% neutrophils, 32% lymphocytes, and 3% blasts. A synovial fluid culture and hemoculture yielded no growth. A bone scintigraphy revealed: a symmetrical blood flow to both ankles; a symmetrical soft-tissue uptake at the knees and ankles, with a prominent early bone uptake; and a symmetrical increased uptake at the mandible, bilateral proximal humeri, both elbows, both forearms, the bilateral femoral heads, the trochanteric region of both femora, the left femoral shaft, the distal femora, the proximal tibiae, the bilateral tibial shafts, and both distal tibiae, all of which favored a bone marrow expansion which might have been related to a leukemic infiltration (Fig. [1](#Fig1){ref-type="fig"}). The real-time quantitative-polymerase chain reaction (RQ-PCR) for *BCR-ABL/ABL* (IS unit) had increased to 21.26%. Testing for mutations in the *BCR-ABL* gene showed a negative result. A bone marrow aspiration revealed 10% myeloblasts. CML blast phase was established due to the highly suspicious evidence of extramedullary blasts at multiple bones and joints. Induction therapy with a 7 + 3 induction regimen (200 mg of cytarabine administered intravenously on days 1--7, plus 15 mg of idarubicin administered intravenously on days 1--3) was prescribed in conjunction with 600 mg of imatinib once daily before switching to 140 mg of dasatinib. His clinical symptoms, including joint pain and fever, improved, and he achieved a complete hematological remission, confirmed by a bone marrow study, 4 weeks after the induction therapy. Unfortunately, he developed dyspnea on exertion after dasatinib treatment for a month, and pleural effusion with pulmonary hypertension were suspected from the dasatinib. We therefore decided to permanently stop administering the medication.Fig. 1Bone scintigraphy showing increased uptake at mandible, bilateral proximal humeri, elbows, forearms, femora, tibiae, knees, and ankles

A month later, in November 2017, he presented to our hospital with severe headaches of 1 week's duration, a low-grade fever, nausea, vomiting, and polyuria. A physical examination revealed hepatosplenomegaly without an abnormal neurological finding. A CBC revealed Hb of 12.8 g/dL, Hct of 39.1%, a WBC count of 20.8 × 10^9^/L (87.1% neutrophils, 9.1% lymphocytes, 2.6% monocytes, 0.7% eosinophils, 0.5% basophils, and no blasts), and a platelet count of 282 × 10^9^/L. A computed tomography (CT) scan of his brain (non-contrast) showed several osteolytic lesions with soft tissue formation at the skull, skull base, and mandible, without intracranial lesions (Fig. [2a](#Fig2){ref-type="fig"}). A film bone survey demonstrated moth-eaten osteolytic bony destruction scattered diffusely on the pelvic bone, skull, spine, and both femurs (Fig. [2b](#Fig2){ref-type="fig"}). His laboratory chemistry revealed serum blood urea nitrogen (BUN) of 64.8 mg/dL, creatinine (Cr) of 4.1 mg/dL, albumin of 4 g/dL, globulin of 4.3 g/dL, total calcium of 17.8 mg/dL, serum parathyroid hormone (PTH) of 9.82 pg/mL (normal 15--65 pg/mL), 25-hydroxyvitamin D of 50.64 ng/mL (normal ≥ 30 ng/mL), and uric acid of 17.4 mg/dL; all other laboratory results were normal. The serum 1,25-dihydroxyvitamin D and PTH-related protein (PTHrP) levels were not available as the relevant tests were not routinely provided by our hospital at that time. A bone marrow aspiration showed multiple stages of the myeloid series with 7% myeloblasts. He was treated with intravenously administered hydration (200 mL/hour of 0.9% normal saline), calcitonin (300 μg administered intravenously every 6 hours for 3 days), and imatinib (600 mg/day). However, as there was a minimal response in his high serum calcium level, we decided to add 20 mg/day of intravenously administered dexamethasone on day 8 of admission. His severe headache symptom improved gradually, and the serum calcium level decreased dramatically to the normal range within a few days. He was then discharged with a serum calcium level of 7.6 mg/dL on day 15 of admission. His hypercalcemic treatment and outcomes are illustrated at Fig. [3](#Fig3){ref-type="fig"}. After that, he was lost to follow-up and died a few weeks after discharge at his home with unknown cause of death. A timeline table of our patient is provided in Additional file [1](#MOESM1){ref-type="media"}.Fig. 2Multiple osteolytic bone lesions on imaging. **a** Computed tomography of brain, revealing several osteolytic bony destruction at skull base; **b** film X-ray, displaying multiple osteolytic lesions on pelvis and both femursFig. 3Timeline treatment for serum calcium levels and white blood cell count of the patient after admission. *IV* intravenous, *WBC* white blood cell

Discussion {#Sec3}
==========

A CML blast crisis is characterized by ≥ 20% of blast cells in the blood or bone marrow, the presence of large clusters of blast cells in a bone marrow biopsy, or the presence of extramedullary blasts. The most common sites of extramedullary involvement by CML are the lymph nodes, bones, and central nervous system \[[@CR7]\]. We presented the first report of a patient with CML with rare coexistence manifestations: leukemic oligoarthritis and, subsequently, symptomatic hypercalcemia.

From a previous study, LA is a very rare complication of both adult and chronic leukemia; however, acute symmetrical polyarthritis mimicking rheumatoid arthritis is the most common presentation in LA \[[@CR8]\]. The typically affected joints are the knees, wrists, and ankles \[[@CR8]\]. The presence of blasts in the synovial fluid has been found in only a third of patients with LA \[[@CR8]\]. The pathogenesis is thought to be leukemic infiltration into the synovial and peri-synovial tissues, such as the periosteum and capsule, which later leads to a synovial reaction, hemorrhaging into the joint from thrombocytopenia, and an immune complex-induced synovitis \[[@CR2]\]. The treatment of choice for LA is definitive therapy for the underlying disease. The LA in this patient was diagnosed by eliminating other causes, including traumatic, crystal-induced, and septic arthritis. Furthermore, we found a few blasts in the synovial fluid, which confirmed the diagnosis of LA, and his symptoms were improved after a 7 + 3 induction regimen plus high-dose imatinib.

CML with hypercalcemia was first reported in 1970 \[[@CR9]\]. In hypercalcemic patients with CML, osteolytic bone can present with varying degrees of severity, ranging from mild to severe osteolysis, all of which can be revealed by a bone survey. There are two major mechanisms for osteolytic bone: humoral mediated and local destruction \[[@CR4]\]. An increase in osteoclastic activity modulated by secreted circulating factors from malignant cells is the mechanism of humoral destruction \[[@CR4]\]. Several related cytokines have been proposed as the cause of bone reabsorption, but the most recently suggested cytokine is PTHrP \[[@CR10]--[@CR14]\]. Some previous studies have reported normal serum PTHrP levels, but PTHrP involvement in the pathogenesis of hypercalcemia could not be excluded since paracrine inducing osteoclastic activity directly to bone is possible \[[@CR15]--[@CR17]\]. For the treatment of PTHrP-related hypercalcemia, imatinib is the most effective medication \[[@CR14]\]. Another proposed humoral-mediated hypercalcemia is primary hyperparathyroidism (PHPT) co-existing in patients with CML \[[@CR18]\]. A reported cause of humoral-mediated hypercalcemia in CML is a calcitriol-related mechanism \[[@CR19]\]. As our patient had normal parathyroid levels, we could exclude PHPT. Although almost all prior cases responded well to tyrosine kinase inhibitors therapy, his serum calcium level and WBC count did not improve after aggressive intravenously administered hydration, intravenously administered calcitonin, and high-dose imatinib therapy. Interestingly, his serum calcium level declined drastically to the normal range within a few days of intravenous corticosteroid administration. We propose that vitamin D-mediated hypercalcemia was probably the mechanism for hypercalcemia in this patient, even if the active form of vitamin D was not tested. Table [1](#Tab1){ref-type="table"} presents the previously reported cases of patients with CML with hypercalcemia, showing the treatment and clinical outcomes for each patient.Table 1Reported cases of chronic myeloid leukemia with hypercalcemiaAuthorsAge/SexOnset of hypercalcemia after CML diagnosisPhase of CMLTreatmentResultsNon-chemotherapyChemotherapyBallard and Marcus (1970) \[[@CR9]\]31/M2.5 monthsBPPREDBUNo response; died 19 days later40/M4 yearsNRHydration, PREDBUNo response; died 24 hours laterLicht *et al*. (1973) \[[@CR20]\]40/F5 yearsBPHydration, hydrocortisone, low calcium dietBUResponse temporary; died 3 weeks laterJoyner *et al*. (1977) \[[@CR5]\]19/F8 monthsAPPRED, IV phosphate, calcitoninMithramycinRapid CR in 8 hours due to calcitonin and mithramycin; later, died34/M8 monthsBPPREDVCR, mithramycinCR due to mithramycin temporary; later, died23/M4 yearsAPCalcitoninMithramycinNo response; later, diedTricot *et al*. (1983) \[[@CR21]\]36/M3 yearsBPCalcitonin, PREDVCRResponse to calcitonin; died a few days laterAttar *et al*. (1988) \[[@CR22]\]62/NA8 yearsBPHydration, corticosteroid, furosemide, calcitoninRubidomycin, cytarabine, thioguanineNo response; later, rapidly diedKubota *et al.* (1989) \[[@CR23]\]43/M4 monthsBPHydration, PRED, forced diuresis, calcitoninVCR, daunomycinCR due to CMT; died 8 months laterTaillan *et al.* (1992) \[[@CR24]\]54/F13 yearsBPConventional therapyHURapid CR; died 1 month laterKubonishi *et al.* (1997) \[[@CR10]\]52/M6 yearsBPPamidronate, PRED, elcatoninVindesine, HU, enocitabine, aclarubicin, 6MP, DAU, DOXTransient response; died 1.5 months laterSharma *et al*. (1998) \[[@CR11]\]56/FNRAPHydration, glucocorticoids, furosemideHU, cytarabineNRQuitt *et al*. (1998) \[[@CR12]\]49/F10 yearsAPHydration, diuretic, calcitonin, steroids, surgeryHU, BUMinimal response; died 24 hours laterKwak *et al*. (2000) \[[@CR13]\]57/M6 yearsBPHydration, corticosteroids, calcitoninHUCR32/M0APHydration, corticosteroids, calcitoninHUCRNadal *et al*. (2001) \[[@CR16]\]78/F4--5 monthsBPHydration, PRED, diuretic, pamidronateVCR, adriamycinRapid CR; died 1 month laterLima *et al*. (2002) \[[@CR25]\]35/F2 yearsBPPRED, pamidronateCyclophosphamide, DOX, VCRCR in 1 week; died 1 month laterMiyoshi *et al*. (2005) \[[@CR14]\]68/F4 yearsBPPRED, diuretic, incadronate, elcatoninEnocitabine, DAU, VCRCR; died 8 months laterNoguchi and Oshimi (2007) \[[@CR26]\]66/M10 yearsBPHydration, PRED, bisphosphonate, elcatoninVCRCR in 3 weeks; died 8 weeks after admissionValizadeh *et al*. (2013) \[[@CR18]\]70/MNRBPParathyroidectomyImatinibNRToro-Tobón *et al*. (2017) \[[@CR4]\]58/M6 yearsBPHydration, calcitonin, zoledronic acidPonatinibCR in 5 days; died 8 months laterThis case (2018)35/M1 yearBPHydration, calcitonin, dexamethasoneImatinibCR in 1 week from dexamethasone; later, lost to follow-up*AP* accelerated phase, *BP* blast phase, BU busulfan, *CML* chronic myeloid leukemia, *CMT* chemotherapy, *CR* complete response, *DAU* daunorubicin, *DOX* doxorubicin, *F* female, *HU* hydroxyurea, *IV* intravenous, *M* male, *NA* not available, *NR* not reported, *PRED* prednisolone, *VCR* vincristine, *6MP* 6-mercaptopurine

Turning to another mechanism of hypercalcemia, local bone destruction resulting from leukemic cell infiltration can explain the elevated serum calcium levels in patients with CML \[[@CR4]\]. This has been proposed as the main mechanism of hypercalcemia when all humoral markers have been excluded. However, we have found that even if serum humoral markers are normal or decreased, humoral-mediated hypercalcemia cannot be totally excluded. Here, we demonstrated the case of a patient with CML blast phase presenting with LA and severe hypercalcemia, which are two exceptional manifestations. Taking all into account, we believe that vitamin D-mediated hypercalcemia is a component of the humoral-mediated hypercalcemia mechanisms in patients with CML.

Conclusions {#Sec4}
===========

Although LA and severe hypercalcemia are extraordinary presentations in patients with CML, the advanced phase of the disease might produce these symptoms. Apart from PTHrP-related hypercalcemia, vitamin D is a mechanism of humoral-mediated hypercalcemia.

Additional file
===============

 {#Sec5}

Additional file 1:Timeline table of the patient. (DOCX 16 kb)
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